Publication | Closed Access

Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study

Rheumatoid DisorderRheumatologySpondyloarthritisRheumatic DiseasesImmunologyOsteoarthritisInflammatory Rheumatic DiseasePaediatric RheumatologyMedicineAxial SpondyloarthritisRheumatoid Arthritis